Celularity (CELU) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Celularity (CELU) overview

Celularity (CELU) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 26.6m and operating profit of USD -61.3m; the year-end share price was 1.11 USD and market capitalisation was USD 32.0m. Celularity is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Celularity's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD -38.1mFY 2025
Share price1.11 USDFY 2025 year end
RevenueUSD 26.6mFY 2025
Operating profitUSD -61.3mFY 2025
Net earningsUSD -91.7mFY 2025
Market capitalisationUSD 32.0mFY 2025 year end

About Celularity

Celularity develops cellular therapies derived from the human placenta and commercializes placental biomaterial products. Its pipeline includes off-the-shelf allogeneic cell therapy candidates, including cenplacel-L, being developed for age-related degenerative diseases and conditions such as immune and infectious diseases and cancer. Marketed products include amniotic membrane allografts and placental connective tissue matrices for soft tissue repair, wound coverage, and reconstructive procedures.

Generate the Celularity report

Celularity is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Celularity and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Celularity

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.